Last-resort drug offered to brain cancer patients

NCT ID NCT06404034

AVAILABLE Disease control Sponsor: Imaging Biometrics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides gallium maltolate (GaM) to adults aged 18 and older with glioblastoma that has returned or is not responding to standard treatments. The goal is to offer a possible treatment option when no others are available. Patients must be able to swallow capsules and have adequate organ function to participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME REFRACTORY GLIOBLASTOMA

Contacts and locations

Locations

Cancer Partners of Nebraska
AVAILABLE

Lincoln, Nebraska, 68516, United States
Northwell Health
AVAILABLE

New York, New York, 10075, United States
University of Miami Sylvester Comprehensive Cancer Center
AVAILABLE

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.